Dermatology News

Janssen Biotech Inc. announced in a press release that the FDA has approved an expanded indication of Stelara for treating adolescents aged 12 years or older with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

In a draft recommendation statement, the U.S. Preventive Services Task Force said there is insufficient evidence to determine if the benefits outweigh the harms from counseling adults about skin self-examinations for the prevention of skin cancer.

A 3-year-old female presented to urgent care with a 1-week history of a pruritic rash on the legs and torso. On the day of her presentation, she additionally developed two new dark brown marks on her right cheek. Her family denied any trauma to the site or exposure to possible new contactants. She was constitutionally well.

A positive basophil activation test result may be a prognostic factor of pediatric chronic urticaria resolution, according to new research published in JAMA Dermatology.

Researchers recommended that children with a medical history of Down syndrome and a personal history of atopy are among a limited group of patients with alopecia areata who should undergo thyroid screening.

The use of guideline-recommended antibiotics, such as trimethoprim/sulfamethoxazole and clindamycin, during incision and drainage of minor Staphylococcus aureus skin and soft tissue infections prevented bacterial colonization and reduced the risk of recurrent infections.

Methotrexate was associated with a higher rate of treatment-related adverse events than tumor necrosis factor inhibitors in a cohort of children with moderate to severe psoriasis.

CHICAGO — Parents of teenagers considering tattoos, piercings or scarification — cutting, burning or branding the skin — are encouraged to inform their pediatrician to facilitate a discussion of consequences and potential risks associated with body modifications, according to a policy statement from the AAP’s Committee on Adolescence.

Encouraging safety outcomes were reported in a cohort of patients with atopic dermatitis who were treated with long-term Eucrisa.

The use of Lactobacillus rhamnosus GG, a probiotic, is unable to prevent asthma or eczema in children at 2 years of age when used in the first 6 months of life.